Clinical Trial Update: Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating safety and efficacy of ATIR101 as an adjunct to haploidentical stem cell transplantation versus post-transplant cyclophosphamide in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ATIR101 (ATIR101)

Snippet

Sponsor: Kiadis Pharma | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2022-05-24